Effects of large doses of furosemide in end-stage chronic renal failure.
Administered orally at 500 mg/day to patients in end-stage chronic renal failure treated by hemodialysis, furosemide significantly decreases the weight gain between dialyses and increases sodium excretion rate. This therapy remains without effect on blood pressure, creatinine clearance and urinary excretion of potassium and nitrogen. Devoid of any side-effects, at least during short periods, the treatment may contribute to achieve better control of sodium and water balance.
D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000652:urine; D005260:Female; D005665:Furosemide / Q000008:administration & dosage* / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D009584:Nitrogen / Q000652:urine; D011188:Potassium / Q000652:urine; D011704:Pyelonephritis / Q000188:drug therapy; D006435:Renal Dialysis
D005665:Furosemide; D003404:Creatinine; D009584:Nitrogen; D011188:Potassium